Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 2:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Non-small Cell Lung Cancer
Interventions
BNT326, Pumitamig
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
11
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 8 more
Conditions
Invasive Mould Infection
Interventions
EL219, Active Comparator- IV Antifungal (LAmB or voriconazole)
Drug
Lead sponsor
Elion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
9
States / cities
Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 6 more
Conditions
Healthy
Interventions
FDC of Macitentan and Tadalafil, Macitentan, Tadalafil
Combination Product · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Hepatitis C, Lung Transplant
Interventions
Epclusa
Drug
Lead sponsor
Pablo Sanchez
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
336
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 259 more
Conditions
COPD
Interventions
Test Product (tiotropium bromide inhalation powder), 18 mcg of Spiriva (Reference Product), Placebo
Combination Product
Lead sponsor
Phargentis SA
Industry
Eligibility
40 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Anderson, South Carolina • Gaffney, South Carolina • Union, South Carolina
Conditions
Opioid-use Disorder, Cocaine Use Disorder
Interventions
Cariprazine 1.5 MG, Placebo
Drug
Lead sponsor
Kyle Kampman
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Biological Availability, Healthy Participants
Interventions
Nirmatrelvir/ ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Terminated Phase 3 Interventional Results available

Ezetimibe in Patients Hypo-responsive to Statins

NCT00965055
Conditions
High Cholesterol, Coronary Artery Disease
Interventions
Ezetimibe, Atorvastatin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Diego, California
Conditions
Smoking, Tobacco Use, Tobacco Smoking
Interventions
Product A, Product B, Product C, Product D, Product E, Product F, Product G, Product H
Other
Lead sponsor
RAI Services Company
Industry
Eligibility
21 Years to 60 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
High Point, North Carolina
Conditions
High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
Interventions
Bone Scan, Cabozantinib S-malate, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Surgical Procedure, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 40 Years
Enrollment
1,122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
181
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 134 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Orange, California • Sacramento, California • Aurora, Colorado + 22 more
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Cirtuvivint, Decitabine and Cedazuridine, Echocardiography Test, Multigated Acquisition Scan
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 17 more
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Proton Beam Radiation Therapy
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 79 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
178
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 128 more
Conditions
Adult Solid Tumor
Interventions
CANscript
Diagnostic Test
Lead sponsor
Mitra RxDx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Timeline
2017 – 2019
U.S. locations
30
States / cities
Gilbert, Arizona • Aurora, Colorado • Norwich, Connecticut + 23 more
Conditions
Tobacco Dependence
Interventions
C-Raven Virtual Tobacco Cessation Counseling, Nicotine Replacement Product, Community Health Worker, Lung Cancer Screening
Behavioral · Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Baltimore, Maryland
Completed Not applicable Interventional Accepts healthy volunteers

Testing Product Messages in Colombia

NCT05783726
Conditions
Obesity
Interventions
Control, Nutriscore Label, Adapted Peruvian Nutrient Label, Guideline Daily Amount Label
Other · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 64 Years
Enrollment
8,086 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Stinging Potential of Sunscreen Products in Human Eyes

NCT02869113
Conditions
Sunscreen Agents
Interventions
BAY98751 (Y65-110), BAY 98751 (Y65-102), BAY 98751 (Y65-106), Standard shampoo mixture (Control)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
St. Petersburg, Florida
Completed Not applicable Interventional Accepts healthy volunteers

CSD201002: Study to Assess Nicotine Uptake From P10 Nicotine Pouches

NCT05081154
Conditions
Smoking, Tobacco Use
Interventions
Product A, Product B, Product C, Product D, Product E, Product F, Product G
Other
Lead sponsor
RAI Services Company
Industry
Eligibility
21 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Belinostat, Carfilzomib, Copanlisib Hydrochloride, Daratumumab, Fludeoxyglucose F-18, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nivolumab, Obinutuzumab, Pembrolizumab, Positron Emission Tomography, Rituximab, Romidepsin, Saline, Trastuzumab
Drug · Biological · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Pembrolizumab, Questionnaire Administration, Radiation Therapy
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
136
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 94 more
Conditions
Infertility
Interventions
gamete treatment
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 89 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Tobacco Use
Interventions
Test Product A, Test Product B, Test Product C, Test Product D, Test Product E, Reference Product F: Subjects' OBMST
Other
Lead sponsor
Altria Client Services LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Bentonville, Arkansas • Springfield, Missouri
Conditions
Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas
Interventions
Neoantigen Peptide Vaccine, Poly ICLC, Blood for immune monitoring
Biological · Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri